Engraftment and transplant-related toxicities of interest
| Toxicities of interest . | Arm A, Bor-HDM . | Arm B, HDM . |
|---|---|---|
| Patients who underwent ASCT, n (%) | 151 (98) | 144 (98.5) |
| PBSC infused (106 CD34/kg), median (Q1-Q3) | 3.45 (2.73-4.71) | 3.38 (2.70-5.00) |
| Duration of hospital stay, median (Q1-Q3), d | 19 (17.0-21.0) | 18 (16.0-20.0) |
| Duration of neutropenia (ANC <0.5 × 109/L), median (Q1-Q3), d | 12 (11.0-14.0) | 12 (11.0-13.0) |
| Duration of thrombocytopenia | ||
| <20 × 109/L, median (Q1-Q3) | 12 d (11.0-14.0) | 12 d (11.0-13.0) |
| <50 × 109/L, median (Q1-Q3) | 16 d (14.0-24.0) | 15 d (14.0-21.0) |
| No. of platelet transfusions, median (Q1-Q3) | 2 (1-3) | 2 (1-3) |
| No. of packed red blood cell transfusions, median (Q1-Q3) | 0 (0-2) | 0 (0-2) |
| Patients with curative antibiotherapy, n (%) | 128 (84.8) | 122 (84.7) |
| Duration of curative antibiotherapy, median (Q1-Q3), d | 8.0 (6.0-12.5) | 9.0 (6.0-13.0) |
| Mucositis any grade, n (%) | 96 (64.0) | 95 (65.5) |
| Mucositis grade 3-4, n (%) | 38 (25.3) | 32 (22.1) |
| Duration of mucositis, median (Q1-Q3), d | 7.0 (5.0-10.0) | 8.0 (4.5-10.0) |
| Gastrointestinal tract/diarrhea, n (%) | 110 (73.3) | 105 (72.4) |
| Dermatologic/allergic reactions, n (%) | 19 (12.7) | 15 (10.3) |
| PNY, n (%) | 38 (25.3) | 15 (10.3) |
| Headache, n (%) | 33 (22.0) | 35 (24.1) |
| Death, n (%) | 1 (0.7) | 0 |
| Toxicities of interest . | Arm A, Bor-HDM . | Arm B, HDM . |
|---|---|---|
| Patients who underwent ASCT, n (%) | 151 (98) | 144 (98.5) |
| PBSC infused (106 CD34/kg), median (Q1-Q3) | 3.45 (2.73-4.71) | 3.38 (2.70-5.00) |
| Duration of hospital stay, median (Q1-Q3), d | 19 (17.0-21.0) | 18 (16.0-20.0) |
| Duration of neutropenia (ANC <0.5 × 109/L), median (Q1-Q3), d | 12 (11.0-14.0) | 12 (11.0-13.0) |
| Duration of thrombocytopenia | ||
| <20 × 109/L, median (Q1-Q3) | 12 d (11.0-14.0) | 12 d (11.0-13.0) |
| <50 × 109/L, median (Q1-Q3) | 16 d (14.0-24.0) | 15 d (14.0-21.0) |
| No. of platelet transfusions, median (Q1-Q3) | 2 (1-3) | 2 (1-3) |
| No. of packed red blood cell transfusions, median (Q1-Q3) | 0 (0-2) | 0 (0-2) |
| Patients with curative antibiotherapy, n (%) | 128 (84.8) | 122 (84.7) |
| Duration of curative antibiotherapy, median (Q1-Q3), d | 8.0 (6.0-12.5) | 9.0 (6.0-13.0) |
| Mucositis any grade, n (%) | 96 (64.0) | 95 (65.5) |
| Mucositis grade 3-4, n (%) | 38 (25.3) | 32 (22.1) |
| Duration of mucositis, median (Q1-Q3), d | 7.0 (5.0-10.0) | 8.0 (4.5-10.0) |
| Gastrointestinal tract/diarrhea, n (%) | 110 (73.3) | 105 (72.4) |
| Dermatologic/allergic reactions, n (%) | 19 (12.7) | 15 (10.3) |
| PNY, n (%) | 38 (25.3) | 15 (10.3) |
| Headache, n (%) | 33 (22.0) | 35 (24.1) |
| Death, n (%) | 1 (0.7) | 0 |
ANC, absolute neutrophil count; PBSC, peripheral blood stem cells.